Skip to main content

Regeneron Pharmaceuticals company profile

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$959.12+0.71%Close 17 Nov 2026 · Market value $102.6B

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Marketed products include EYLEA HD, Libtayo, Praluent, Kevzara, Dupixent (through collaboration), and Lynozyfic, among others. The company uses proprietary platforms, including Trap technology and VelociSuite, to discover and produce fully human antibodies, bispecific antibodies, and gene and RNA-based therapies. It operates across the United States and, through collaborators and licensees such as Sanofi and Bayer, in markets outside the United States.

A summary of the business section of the company's latest annual report, filed 4 Feb 2026.

Company facts

TickerREGN · Nasdaq
SectorPharmaceuticals
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK872589
Latest annual report10-K, filed 4 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Leonard S. Schleifer, M.D., Ph.D.Bd. Co-Chair, President & CEO · Director1.7M · 95%Shares withheld for tax, 31 Dec 2025
Andrew J. Murphy, Ph.D.Co-Chief Scientific Officer246KGift, 3 Nov 2026
Joseph J. LaRosaEVP General Counsel and Secret183KOption exercise, 2 Nov 2026
Daniel P. Van PlewEVP & General Mgr, Industrial106KShares withheld for tax, 9 Dec 2025
Christopher FenimoreEVP Finance CFO93.9KOption exercise, 2 Nov 2026
George L. SingDirector69.2KOption exercise, 2 Nov 2026
George D. Yancopoulos, M.D., Ph.D.Bd. Co-Chair, President & CSO · Director42.8K · 2.4%Option exercise, 31 Dec 2025
Christine A. PoonDirector41.2KOption exercise, 2 Nov 2026
Huda Y. Zoghbi, M.D.Director30.7KOption exercise, 3 Nov 2026
Arthur F. RyanDirector26.6KSale under a 10b5-1 plan, 2 Jul 2026
Michael S. Brown, M.D.Director19.1KOption exercise, 30 Oct 2026
Bonnie L. Bassler, Ph.D.Director17.9KSale under a 10b5-1 plan, 7 Jan 2026
Joseph L. Goldstein, M.D.Director13.0KGrant or award, 2 Jan 2026
N. Anthony Coles, M.D.Director10.7KGrant or award, 2 Jan 2026
Craig B. Thompson, M.D.Director8.8KGrant or award, 2 Jan 2026
Kathryn Guarini, Ph.D.Director6.6KOption exercise, 30 Oct 2026
David P. Schenkein, M.D.Director6.6KGrant or award, 2 Jan 2026
Pitofsky JasonSVP Controller—Option exercise, 4 Nov 2026
McCourt MarionEVP Commercial—Sale under a 10b5-1 plan, 30 Oct 2026
STAHL NEILEVP Research and Development—Shares withheld for tax, 16 Dec 2024

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

REGN in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.